myeloma (MM) (1) . IPH2101 is a fully human monoclonal antibody that blocks HLA--C binding KIR2D receptors (KIR2DL/DS--1, --2 --3) expressed on the surface of NK--cells, enhancing their cytotoxicity against tumor targets by preventing HLA class I mediated inhibitory KIR signaling. In vitro studies confirm that IPH2101 enhances NK--cell killing of MM--cell lines (2) , while data from KIR ligand--mismatched allogeneic stem cell transplants (SCT)(3) and infusions of KIR ligand--mismatched allogeneic NK--cells prior to autologous SCT(4) suggest a potential therapeutic benefit. Since deteriorated NK--cell function tends to occur in later clinical stages of MM (5), we hypothesized that smoldering multiple myeloma (SMM) may be a unique timepoint for NK--cell based interventions prior to evasion of host immune system by tumor cells.
We conducted a two--stage phase II clinical trial in SMM patients (Table  1) by administering IPH2101 at 1 mg/kg intraveneously every other month for 6 cycles. A total of 9 SMM patients were enrolled onto the first stage of the study at the NIH Clinical Center between December 2010 and May 2011. After completion of the first stage, the study was terminated due to lack of patients meeting the primary objective (50% decline in M--protein). Clinical response rates during the first 6 cycles of IPH2101 yielded 1/9 (11%) patients with minimal response (MR; >25% and <50% decrease in M--protein), 6/9 (66%) patients with stable disease (SD), 1/9 (11%) with biochemical progression (BP), and 1/9 (11%) patients with clinical progression to symptomatic MM. During the follow--up period (median follow--up 32 months, 8--37), two additional patients (PT #5 and #9) progressed to symptomatic MM within 3--6 months after IPH2101 infusions had stopped. IPH2101 infusions were well tolerated with no grade 3 or 4 toxicities reported. The most common toxicities included: constitutional (chills, fever) -11.1% grade 1 and 22% grade 2, GI related (diarrhea, nausea, abdominal discomfort) -22.2% grade 1, liver function test elevation (ALT, AST increases) -11.1% grade 2, fatigue -11.1% grade 1, and creatinine increase -11.1% grade 1.
To exclude the lack of clinical responses observed in this study was related to dysfunctional patient NK--cells, we assessed their ability to recognize the gold standard NK--cell target K562. As shown in Figure  1A , degranulation by patient NK--cells vs. K562 targets was similar to that of healthy subjects. To evaluate whether clinical outcome was related to other NK--cell properties, we measured the absolute number of all NK--cells and the number of NK that express KIR2D as their only HLA class I--binding inhibitory receptor (KIR2D single positive (SP) NK--cells) ( Table 1 ). The latter NK--cell subset would be predicted to be fully augmented against MM--cells following KIR blockade with IPH2101. However, neither of these parameters was found to be associated with disease outcome in our cohort (Data not shown).
Another factor that potentially impacts the efficacy of this antibody is how efficiently IPH2101 blocks KIR2D on NK--cells. We therefore measured the proportion of free ligand--bindable KIR2D receptors throughout the trial using previously described methods(6, 7). Ligand--bindable KIR2D expression was found to decrease to 0% in all 9 subjects 24 hours after first infusion ( Figure 1B) . In six out of eight patients, this level was maintained at <50% compared to baseline when measured prior to each subsequent IPH2101 infusion, suggesting that IPH2101 treatment was able to significantly reduce ligand--bindable KIR2D levels for up to 60 days following each infusion in most patients. Among the two patients with ≥50% ligand-- Recent evidence from a randomized phase III study shows that early treatment with lenalidomide and dexamethasone improves time to progression and overall survival in high--risk SMM patients when compared to observation (8) . Several studies are currently exploring platforms of therapy in SMM patients (9) . We assessed the potential impact of treating "early myeloma" using an immune--based strategy with IPH2101 in a patient cohort that presumably had preserved NK--cell function. Our results show no patients (n=0/9) obtained a 50% reduction in M--protein concentration and the study did not continue to the second stage of enrollment due to lack of efficacy as defined by our criteria. One possible explanation for lack of clinical response may be that MM--cells are poorly recognized by patient NK--cells.
However, we consider this explanation unlikely since NK--cell function was preserved in our cohort ( Figure   1A ) and previous reports have demonstrated that MM--cells from patients with early myeloma(10) have sufficient expression of ligands to activate NK--cell receptors. The observation that NK--cells can kill MM--cells following HLA class I blockade (11) , further supports the notion that NK--cells are capable of recognizing MM--cells. Using the previously described indirect method to measure "KIR occupancy"(6, 7), our data shows IPH2101 infusions effectively decreased free KIR2D receptor levels on NK--cells for up to 8 weeks ( Figure 1B) . However, such methodology assumes that KIR2D surface levels on NK--cells are maintained at a constant steady state before and after IPH2101 infusion. Recognizing this limitation, we proposed the term "ligand--bindable KIR2D expression" rather than "KIR occupancy" used in previous publications. This terminology avoids the assumption that all reductions in NK--cell KIR2D expression occur as a consequence of IPH2101 antibody "occupying" KIR2D, but rather, could potentially be attributed to decreased expression of KIR2D molecules on NK--cells (decreased production or loss of existing KIR2D receptors) or elimination of KIR2D expressing NK--cells.
Although our study showed no clinical response to single agent IPH2101, we cannot exclude that KIR2D blockade given with other agents (e.g. lenalidomide) to bolster NK--cell cytotoxicity or in the setting of adoptive transfer of allogeneic or ex vivo expanded autologous NK--cells may generate clinically significant responses in future trials. The proportion of ligand--bindable KIR2D+ NK--cells was measured in peripheral blood prior to first infusion (pre--C1D1), one day after first infusion (C1D2) and then before each infusion of IPH2101 (n=8). Six (6) out of eight (8) patients show less than 50% ligand--bindable KIR2D+ NK--cells in peripheral blood throughout the trial. The following patients had missing data point assessment: patient 4 (pre--C6D1), patients 6 and 7 (pre--C5D1), and patient 8 (pre--C3D1 and --C6D1). No pre--treatment sample was obtained for patient 9.
